Regulatory peptide receptors in human hepatocellular carcinomas.
PDF (332K)
+2 authors
Journal: 1999/December - Gut
ISSN: 0017-5749
PUBMED: 10517918
Abstract:
BACKGROUND
Overexpression of regulatory peptide receptors in selected human tumours is of diagnostic and therapeutic relevance.
OBJECTIVE
To evaluate the expression of somatostatin, vasoactive intestinal peptide (VIP), substance P, cholecystokinin (CCK) A and B, and neurotensin receptors in hepatocellular carcinoma (HCC).
METHODS
In vitro receptor autoradiography for the various peptide receptors using selective iodinated radioligands on tissue sections in 59 cases of HCC.
RESULTS
41% of HCC expressed somatostatin receptors; 47% expressed VIP receptors. VIP receptors were always identified in non-neoplastic liver tissue. Substance P receptors were only identified in 5% of HCC but in the majority of their peritumorous and intratumorous vessels. CCK-A and -B and neurotensin receptors were not detected in HCC. The somatostatin receptors showed high affinity for somatostatin and octreotide. The VIP receptors had high affinity for VIP, pituitary adenylate cyclase activating peptide (PACAP) 27, and a VIP1 selective analogue, suggesting the presence of VIP1/PACAP II type receptors. PACAP I receptors were identified in two cases. Substance P receptors were all of the NK1 subtype. The density of somatostatin receptors in HCC was low compared with the density found in liver metastases of neuroendocrine tumours. The VIP receptor density was always lower in HCC than in adjacent liver tissue.
CONCLUSIONS
Somatostatin, VIP, and substance P may have a receptor mediated role in HCC. Substance P receptors may be involved in regulation of tumour associated blood flow; somatostatin receptors and VIP receptors may mediate tumour growth. Diagnostic and therapeutic evaluation of somatostatin and VIP analogues may be of interest in receptor positive HCC.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(24)
References
(20)
Diseases
(2)
Chemicals
(9)
Organisms
(1)
Processes
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Gut 45(5): 766-774
PMID: 10517918

Regulatory peptide receptors in human hepatocellular carcinomas

Abstract

BACKGROUND—Overexpression of regulatory peptide receptors in selected human tumours is of diagnostic and therapeutic relevance.
AIMS—To evaluate the expression of somatostatin, vasoactive intestinal peptide (VIP), substance P, cholecystokinin (CCK) A and B, and neurotensin receptors in hepatocellular carcinoma (HCC).
METHODS—In vitro receptor autoradiography for the various peptide receptors using selective iodinated radioligands on tissue sections in 59 cases of HCC.
RESULTS—41% of HCC expressed somatostatin receptors; 47% expressed VIP receptors. VIP receptors were always identified in non-neoplastic liver tissue. Substance P receptors were only identified in 5% of HCC but in the majority of their peritumorous and intratumorous vessels. CCK-A and -B and neurotensin receptors were not detected in HCC. The somatostatin receptors showed high affinity for somatostatin and octreotide. The VIP receptors had high affinity for VIP, pituitary adenylate cyclase activating peptide (PACAP) 27, and a VIP1 selective analogue, suggesting the presence of VIP1/PACAP II type receptors. PACAP I receptors were identified in two cases. Substance P receptors were all of the NK1 subtype. The density of somatostatin receptors in HCC was low compared with the density found in liver metastases of neuroendocrine tumours. The VIP receptor density was always lower in HCC than in adjacent liver tissue.
CONCLUSIONS—Somatostatin, VIP, and substance P may have a receptor mediated role in HCC. Substance P receptors may be involved in regulation of tumour associated blood flow; somatostatin receptors and VIP receptors may mediate tumour growth. Diagnostic and therapeutic evaluation of somatostatin and VIP analogues may be of interest in receptor positive HCC.


Keywords: somatostatin receptors; vasoactive intestinal peptide receptors; substance P receptors; receptor autoradiography; tumour vasculature

Full Text

The Full Text of this article is available as a PDF (332K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med. 1995 Oct;36(10):1825–1835. [PubMed] [Google Scholar]
  • Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998 Feb 7;351(9100):417–418. [PubMed] [Google Scholar]
  • Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, Reading CC, Moertel C. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990 Sep 15;50(18):5969–5977. [PubMed] [Google Scholar]
  • Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med. 1995 Oct;36(10):1846–1853. [PubMed] [Google Scholar]
  • Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997 Apr 1;57(7):1377–1386. [PubMed] [Google Scholar]
  • Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer. 1995 Jun 9;61(6):786–792. [PubMed] [Google Scholar]
  • Przedborski S, Levivier M, Cadet JL. Neurotensin receptors in human meningiomas. Ann Neurol. 1991 Nov;30(5):650–654. [PubMed] [Google Scholar]
  • Reubi JC, Waser B, Friess H, Büchler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998 Apr;42(4):546–550.[PMC free article] [PubMed] [Google Scholar]
  • Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991 Nov;12(4):450–482. [PubMed] [Google Scholar]
  • Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994 Oct 27;331(17):1116–1121. [PubMed] [Google Scholar]
  • Behr TM, Jenner N, Radetzky S, Béhe M, Gratz S, Yücekent S, Raue F, Becker W. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998 Apr;25(4):424–430. [PubMed] [Google Scholar]
  • Zhao M, Laissue JA, Zimmermann A. "Neuroendocrine" differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol Histopathol. 1993 Oct;8(4):617–626. [PubMed] [Google Scholar]
  • Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998 Mar;42(3):442–447.[PMC free article] [PubMed] [Google Scholar]
  • EDMONDSON HA, STEINER PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954 May;7(3):462–503. [PubMed] [Google Scholar]
  • Reubi JC, Perrin MH, Rivier JE, Vale W. High affinity binding sites for a somatostatin-28 analog in rat brain. Life Sci. 1981 May 11;28(19):2191–2198. [PubMed] [Google Scholar]
  • Reubi JC. New specific radioligand for one subpopulation of brain somatostatin receptors. Life Sci. 1985 May 13;36(19):1829–1836. [PubMed] [Google Scholar]
  • Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. Development of high affinity selective VIP1 receptor agonists. Peptides. 1997;18(10):1539–1545. [PubMed] [Google Scholar]
  • Reubi JC, Waser B, Läderach U, Stettler C, Friess H, Halter F, Schmassmann A. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology. 1997 Apr;112(4):1197–1205. [PubMed] [Google Scholar]
  • Collier NA, Weinbren K, Bloom SR, Lee YC, Hodgson HJ, Blumgart LH. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet. 1984 Mar 10;1(8376):538–540. [PubMed] [Google Scholar]
  • Schindel DT, Grosfeld JL. Hepatic resection enhances growth of residual intrahepatic and subcutaneous hepatoma, which is inhibited by octreotide. J Pediatr Surg. 1997 Jul;32(7):995–998. [PubMed] [Google Scholar]
Institute of Pathology, University of Berne, Berne, Switzerland.
Institute of Pathology, University of Berne, Berne, Switzerland.
Copyright notice

Abstract

BACKGROUND—Overexpression of regulatory peptide receptors in selected human tumours is of diagnostic and therapeutic relevance.
AIMS—To evaluate the expression of somatostatin, vasoactive intestinal peptide (VIP), substance P, cholecystokinin (CCK) A and B, and neurotensin receptors in hepatocellular carcinoma (HCC).
METHODS—In vitro receptor autoradiography for the various peptide receptors using selective iodinated radioligands on tissue sections in 59 cases of HCC.
RESULTS—41% of HCC expressed somatostatin receptors; 47% expressed VIP receptors. VIP receptors were always identified in non-neoplastic liver tissue. Substance P receptors were only identified in 5% of HCC but in the majority of their peritumorous and intratumorous vessels. CCK-A and -B and neurotensin receptors were not detected in HCC. The somatostatin receptors showed high affinity for somatostatin and octreotide. The VIP receptors had high affinity for VIP, pituitary adenylate cyclase activating peptide (PACAP) 27, and a VIP1 selective analogue, suggesting the presence of VIP1/PACAP II type receptors. PACAP I receptors were identified in two cases. Substance P receptors were all of the NK1 subtype. The density of somatostatin receptors in HCC was low compared with the density found in liver metastases of neuroendocrine tumours. The VIP receptor density was always lower in HCC than in adjacent liver tissue.
CONCLUSIONS—Somatostatin, VIP, and substance P may have a receptor mediated role in HCC. Substance P receptors may be involved in regulation of tumour associated blood flow; somatostatin receptors and VIP receptors may mediate tumour growth. Diagnostic and therapeutic evaluation of somatostatin and VIP analogues may be of interest in receptor positive HCC.


Keywords: somatostatin receptors; vasoactive intestinal peptide receptors; substance P receptors; receptor autoradiography; tumour vasculature

Abstract
Full Text
Selected References
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.